Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand

Surgery

Volumn 125, Issue 1, 1999, Pages 73-84

  Bernstorff, Wolfram V ^a   Spanjaard, Remco A ^a,c   Chan, Allen K ^a   Lockhart, Diane C ^a   Sadanaga, Noriaki ^a   Wood, Isabelle ^a   Peiper, Matthias ^a,d   Goedegebuure, Peter S ^a   Eberlein, Timothy J ^a,b  

^a Division of Surgical Oncology   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR ESCAPE;

EID: 0032893304     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70291-6     Document Type: Article

References (44)

1. 1. Janes RH, Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell LH, et al. National patterns of care for pancreatic cancer. Ann Surg 1996;223:261-72.
2. 2. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, et al. p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 1993;8:289-98.
3. 3. Fleuren JG, Gorter A, Kuppen PJK, Litvinov S, Warnaar SO. Tumor heterogeneity and immunotherapy of cancer. Immunol Rev 1995;145:91-122.
4. 4. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991;51:6372-80.
5. 5. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg S, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
6. - melanoma cells are relatively resistant to CD3-mediated T-cell lysis. Int J Cancer 1990;46:475-80.
7. 7. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
8. 8. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J Clin Invest 1993;92:2569-76.
9. 9. Yagita M, Seppo A, Renkonen O, Saksela E. Deacetylase 10 activity of human tumor cells producing immunosuppressive aminosugars: its possible role in resistance to cell-mediated cytotoxicity. Cancer Res 1993;53:5600-4.
10. 2. Cell Immunol 1989;123:384-95.
11. 11. Gimmi CD, Morrisson BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, et al. Breast cancer-associated antigen, DF3/MUCI, induces apoptosis of activated human T cells. Nat Med 1996;2:1367-70.
12. 12. O'Mahony AM, O'Sullivan GC, O'Connell J, Cotter TG, Collins JK. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 1993;151:4847-56.
13. 13. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
14. 14. Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 1996;157:1919-25.
15. 15. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
16. 16. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
17. 17. Rieux-Laucat F, Le Deist F, Hivoz C, Roberts IAG, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
18. 18. Peng SL, Robert ME, Hayday AC, Craft J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 1996;184:1149-54.
19. 19. Walker PR, Saas P, Dietrich P-Y. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997;158:4521-4.
20. 20. Takagi A, Imai A, Horibe S, Ohno T, Tamaya T. Lack of evidence for expression of Fas ligand in Fas-bearing tumors. Oncol Rep 1998;5:377-80.
21. 21. Peiper M, Nagoshi M, Patel D, Fletcher JA, Goedegebuure PS, Eberlein TJ. Human pancreatic cancer cells (MPanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion. Int J Cancer 1997;71:993-9.
22. 22. Mariani SM, Matiba B, Bäumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteinases. Eur J Immunol 1995;25:2303-7.
23. 23. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, et al. Human lung carcinoma express Fas ligand. Cancer Res 1997;57:1007-12.
24. 24. Fraker PJ, King LE, Lill-Elghanian D. Quantification of apoptotic events in pure and heterogeneous populations of cells using the flow cytometer. Methods Cell Biol 1995;46:57-76.
25. 25. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
26. 26. Keane MM, Ettenberg SA, Lowry GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996;56:4791-8.
27. 27. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, et al. Lymphocyte apoptosis induced by CD95(Apo-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med 1996;2:1361-6.
28. 28. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
29. 29. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinoma. Proc Natl Acad Sci 1997;94:6420-5.
30. 30. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995;14:1129-35.
31. 31. Hayashi H, Tatetebe S, Osaki M, Goto A, Suzuki Y, Ito H. Expression of Fas antigen and its mediation of apoptosis in human gastric cancer cell lines. Jpn J Cancer Res 1997;88:49-55.
32. 32. Mori S, Murakami-Mori K, Jewett A, Nakamura S, Bonavida B. Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Cancer Res 1996;56:1874-9.
33. 33. Möller P, Koretz K, Leithäuser F, Brüderlein S, Henne C, Quentmeier A, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994;57:371-7.
34. 34. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
35. 35. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Nat Med 1996;2:317-22.
36. 36. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997;240:240-4.
37. 37. Arai H, Chan SY, Bishop DK, Nabel GJ. Inhibition of the alloantibody response by CD95 ligand. Nat Med 1997;3:843-8.
38. 38. Seino K-I, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165-70.
39. 39. Kang S-M, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997;3:738-43.
40. 40. Bulfone-Paus S, Ungureanu D, Pohl T, Lindner G, Paus R, Rückert R, et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 1997;3:1124-8.
41. 41. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J Clin Invest 1994;94:954-64.
42. 42. Egle A, Villunger A, Kos M, Böck G, Gruber J, Auer B, et al. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-α2. Eur J Immunol 1996;26:3119-26.
43. 43. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel M-T. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 1997;89:783-9.
44. 44. Ziegler A, Luedke GH, Fabbro D, Altmann K-H, Stahel RA, Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the bcl-2 coding sequence. J Natl Cancer Inst 1997;89:1027-36.